Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1444707
This article is part of the Research Topic EGFR-TKIs for Lung Cancer Treatment: Development, Application, and Side Effects View all 5 articles

Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study

Provisionally accepted
Hongxin Li Hongxin Li 1Wen Zhao Wen Zhao 2Caiyun Chang Caiyun Chang 3*Tiantian Xuan Tiantian Xuan 4Chengjun Wang Chengjun Wang 2Rongyu Zhang Rongyu Zhang 2Chuang Yang Chuang Yang 2*Jian Wang Jian Wang 2*Cuihua Yi Cuihua Yi 2*Xiuwen Wang Xiuwen Wang 2*Yu Shuwen Yu Shuwen 1*Jisheng Li Jisheng Li 2*
  • 1 Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
  • 2 Department of Medical Oncology, Qilu Hospital, Shandong University, Jinan, China
  • 3 Jinan Disease Prevention and Control Center, Jinan, Shandong Province, China
  • 4 Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China

The final, formatted version of the article will be published soon.

    Background Aumolertinib demonstrated superior progression-free survival (PFS) and a well-tolerated toxicity profile to gefitinib in front-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in the AENEAS trial. However, patient-reported outcomes (PROs) of aumolertinib have not been reported. Methods In this real-world study, efficacy was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. PROs were evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (QLQ-C30) and EORTC Quality of Life lung cancer-specific module (QLQ-LC13) in advanced NSCLC patients receiving aumolertinib as initial therapy. Prespecified key symptoms were cough, hemoptysis, dyspnea, sore mouth or tongue, dysphagia, hair loss, tingling hands or feet, chest pain, arm or shoulder pain and pain of other sites. Results Totally, 33 patients were included and 23 patients had efficacy information up to Jan 2024. The median follow-up time was 264 days (interval: 36-491 days). The objective response rate and disease control rate was 65.2% and 91.3%, respectively. EORTC QLQ-LC30 showed general health status scale and functional scales increased and symptom scales decreased during aumolertinib treatment. Symptom scales assessed by EORTC QLQ-LC13 showed coughing, sore mouth or tongue, tingling hands or feet, cheat pain, arm or shoulder pain and other pain improvements were both clinically and statistically significant after 6-month aumolertinib treatment (P<0.05). Conclusions In this real-world study, aumolertinib showed comparable disease control rate and objective response rate as reported in AENEAS trial for advanced NSCLC patients with EGFR sensitizing mutation. Aumolertinib treatment improved PROs, further supported the its first-line in clinical practice.

    Keywords: Non-small cell lung cancer, epidermal growth factor receptor, aumolertinib, Patientreported outcomes, efficacy

    Received: 06 Jun 2024; Accepted: 12 Aug 2024.

    Copyright: © 2024 Li, Zhao, Chang, Xuan, Wang, Zhang, Yang, Wang, Yi, Wang, Shuwen and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Caiyun Chang, Jinan Disease Prevention and Control Center, Jinan, 250000, Shandong Province, China
    Chuang Yang, Department of Medical Oncology, Qilu Hospital, Shandong University, Jinan, China
    Jian Wang, Department of Medical Oncology, Qilu Hospital, Shandong University, Jinan, China
    Cuihua Yi, Department of Medical Oncology, Qilu Hospital, Shandong University, Jinan, China
    Xiuwen Wang, Department of Medical Oncology, Qilu Hospital, Shandong University, Jinan, China
    Yu Shuwen, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China
    Jisheng Li, Department of Medical Oncology, Qilu Hospital, Shandong University, Jinan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.